Stable Isotope Labelled Siltuximab Biosimilar – Anti-IL6 mAb – Research Grade

Reference: PX-TA1029-SIL-1MG


Product type


Expression system


Product nameStable Isotope Labelled Siltuximab Biosimilar - Anti-IL6 mAb - Research Grade
SourceDrugBank DB09036
Expression systemMammalian cells
Molecular weight145kDa
BufferPBS pH7.5
Delivery conditionBlue Ice
Delivery Time3-5 days if in stock; 5-8 weeks if production needed
Storage condition4°C for short term; -20°C for long term
Aliases /SynonymsSiltuximab
Related ProductsPX-P4557
NoteFor research use only. Not suitable for clinical or therapeutic use.
ClonalityMonoclonal Antibody
LabellingArginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99%
Isotopic Enrichment99%
Stability1 year

General information on Siltuximab Therapeutic Antibody

The Siltuximab antibody is a chimeric mouse/human therapeutic antibody obtained from mouse hybridoma. It was designed to act as an anti-inflammatory and immunosuppressant drug, and it has been licensed for therapeutic use by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of Multicentric Castleman’s disease (MCD). MCD is a rare condition affecting lymph nodes and related tissues systemically. The disease is often associated with infections mediated by human herpesvirus 8 (HHV-8) and human immunodeficiency virus (HIV). It may manifest mild symptoms in some patients but become life-threatening in others. Siltuximab is also currently under investigation for oncological conditions such as multiple myeloma, renal cell carcinoma, and neoplasm.

Siltuximab is one of several IgG1 antibodies known to bind the human interleukin 6 (IL-6) molecule, a soluble glycoprotein with a key role in pro-inflammatory responses. IL-6 is one of the main proinflammatory cytokines overexpressed in multiple pathologies (e.g. viral infections, rheumatoid arthritis, MCD, etc.). It is typically produced by T cells, B cells, monocytes, fibroblasts, and endothelial cells and it binds to a membrane-bound or soluble interleukin 6 receptor (IL6R). By binding its receptor, IL-6 has been shown to trigger different responses such as stimulate B cell proliferation, induce production of vascular endothelial growth factor (VEGF), and cause immune system dysregulation, among others.

The exacerbated immune response known as “cytokine storm” or cytokine release syndrome has been recently linked to fatal or poor outcomes in the COVID-19 disease. The upper respiratory tract infection with a new strain of coronavirus – SARS-CoV-2 – may lead to this aberrant immune response which has been shown to cause extensive and irreversible lung damage. Siltuximab for COVID-19 treatment in mono or combinational regimen is currently being evaluated for efficiency and safety in clinical trials. Siltuximab cost information is available below. This product is for research use only.


There are no reviews yet.


Be the first to review “Stable Isotope Labelled Siltuximab Biosimilar – Anti-IL6 mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Contact us

Send us a message from the form below

    Cart (0 Items)

    Your cart is currently empty.

    View Products